Huadong Pharmaceutical announced on October 27 that the GLP-1/GIP dual-target long-acting agonist HDM1005 injection independently developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently completed random administration of participants in the first phase III clinical studies of obstructive sleep apnea combined with obesity or overweight in China. This marks that HDM1005 has officially entered phase III clinical phase for this indication.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.